Brief: Bioxytran Completes Randomized Clinical Trial For Its Broad-Spectrum Antiviral Drug
29/10/2025 14:37
Bioxytran Inc BIXT.PK: BIOXYTRAN COMPLETES RANDOMIZED CLINICAL TRIAL FOR ITS BROAD-SPECTRUM ANTIVIRAL DRUG Source text: ID:nGNX7bHyq8 Further company coverage: BIXT.PK
Recent news on Bioxytran
See all newsUS officials pressed China on rare earths, farm goods commitments, Bessent says (updated)
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst (updated)
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
Brief: Bioxytran Inc Reports Positive Phase 1B/2A Clinical Study Results For Prolectin-M, Broad-Range Antiviral Drug In Mild To Moderate Covid-19
Brief: Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance With Prolectin-Mbioxytran